KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Revenue: 2009-2025

Historic Revenue for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $1.1 billion.

  • Jazz Pharmaceuticals' Revenue rose 6.74% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 4.37%. This contributed to the annual value of $4.1 billion for FY2024, which is 6.12% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Revenue stood at $1.1 billion, which was up 25.42% from $897.8 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Revenue peaked at $1.1 billion during Q3 2025, and registered a low of $607.6 million during Q1 2021.
  • Moreover, its 3-year median value for Revenue was $992.0 million (2023), whereas its average is $992.7 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Revenue spiked by 39.48% in 2021, and later fell by 12.31% in 2025.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Revenue stood at $896.7 million in 2021, then increased by 8.41% to $972.1 million in 2022, then increased by 4.10% to $1.0 billion in 2023, then climbed by 7.53% to $1.1 billion in 2024, then grew by 6.74% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $897.8 million for Q2 2025, and $1.1 billion during Q4 2024.